Brief: UCB Said Dapirolizumab Pegol Shows Potential To Reduce Flare Rates
04/06/2026 06:22
BRIEF-UCB Said Dapirolizumab Pegol Shows Potential To Reduce Flare Rates June 4 (Reuters) - Ucb SA UCB.BR:
DAPIROLIZUMAB PEGOL SHOWS POTENTIAL TO REDUCE FLARE RATES AND MAINTAIN DISEASE CONTROL IN SYSTEMIC LUPUS ERYTHEMATOSUS
PHASE 3 PHOENYCS GO STUDY SHOWED DZP PLUS STANDARD OF CARE WAS ASSOCIATED WITH SUSTAINED DISEASE CONTROL AT LOWER GLUCOCORTICOID DOSES THROUGH WEEK 48 COMPARED WITH PLACEBO PLUS STANDARD OF CARE
Further company coverage: UCB.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on UCB SA
See all newsEurope Research Roundup: Banca Generali, Ferrari, Prysmian
Barclays downgrades UCB after rally, sees limited upside
Brief: UCB Says CIMZIA Delivered Consistent Effect In Rheumatoid Arthritis
Brief: UCB Said Dapirolizumab Pegol Shows Potential To Reduce Flare Rates
Brief: UCB Presents Bimzelx Data At Eular 2026